<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Sources – Mallinckrodt / Endo / Keenova / Par Health</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta
    name="description"
    content="Linked public sources used to build the Mallinckrodt / Endo / Keenova / Par Health overview, timeline and litigation summary."
  />
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header>
  <div class="nav-inner">
    <div class="brand">
      <div class="brand-logo"></div>
      <div>
        <div class="brand-text-main">Keenova / Par Health</div>
        <div class="brand-text-sub">Sources</div>
      </div>
    </div>
    <button class="nav-toggle" aria-label="Toggle navigation">
      <span></span>
      <span></span>
    </button>
    <nav class="nav-links">
      <a href="index.html">Overview</a>
      <a href="timeline.html">Timeline</a>
      <a href="litigation.html">Litigation</a>
      <a href="sources.html" class="nav-cta">Sources</a>
    </nav>
  </div>
</header>

<main class="page-shell">
  <section class="section">
    <div class="section-header">
      <div class="section-kicker">Public Record</div>
      <h2 class="section-title">Key sources used on this site</h2>
      <p class="section-subtitle">
        Factual statements in the overview, timeline and litigation pages are intended to be traceable to one or more of these
        links. This is a curated list, not an exhaustive bibliography.
      </p>
    </div>

    <div class="section-body">
      <div class="subsection">
        <div class="subsection-title">Bankruptcy, settlements and trust structures</div>
      </div>
      <ul class="sources-list">
        <li>
          <a href="https://www.opioidmasterdisbursementtrust.com/Mallinckrodt" target="_blank" rel="noopener noreferrer">
            Mallinckrodt Opioid Master Disbursement Trust II (MDT&nbsp;II) – official site
          </a>
          <span>Describes MDT&nbsp;II’s role as a “hub” trust, its payment schedule and its relationships to sub-trusts and creditor classes.</span>
        </li>
        <li>
          <a href="https://oag.ca.gov/opioids" target="_blank" rel="noopener noreferrer">
            California Attorney General – National Opioids Settlements &amp; opioid bankruptcies
          </a>
          <span>Summarizes Mallinckrodt’s and Endo’s opioid settlement obligations and trust arrangements.</span>
        </li>
        <li>
          <a href="https://ncdoj.gov/attorney-general-josh-stein-announces-updated-settlement-with-opioid-manufacturer-mallinckrodt/" target="_blank" rel="noopener noreferrer">
            North Carolina Attorney General – Mallinckrodt settlement details
          </a>
          <span>Provides additional structure and payment information for Mallinckrodt’s opioid settlement framework.</span>
        </li>
        <li>
          <a href="https://endotrust.com/" target="_blank" rel="noopener noreferrer">
            Endo Public Opioid Trust – official site
          </a>
          <span>Explains the beneficiaries, distribution mechanics and governance of the Endo Public Opioid Trust.</span>
        </li>
        <li>
          <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/mallinckrodt-gets-approval-restructuring-1-billion-cut-opioid-settlement-2023-10-10/" target="_blank" rel="noopener noreferrer">
            Reuters – “Court OKs Mallinckrodt restructuring, $1 billion cut to opioid settlement” (Oct&nbsp;10&nbsp;2023)
          </a>
          <span>Details court approval of Mallinckrodt’s second plan, including reductions in opioid obligations and cancelled equity.</span>
        </li>
        <li>
          <a href="https://www.davispolk.com/experience/mallinckrodt-emerges-chapter-11" target="_blank" rel="noopener noreferrer">
            Davis Polk – “Mallinckrodt emerges from chapter 11” (Nov&nbsp;16&nbsp;2023)
          </a>
          <span>Summarizes Mallinckrodt’s post-emergence capital structure and take-back debt.</span>
        </li>
        <li>
          <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-endo-receives-us-court-approval-bankruptcy-restructuring-2024-03-19/" target="_blank" rel="noopener noreferrer">
            Reuters – “Drugmaker Endo receives US court approval for bankruptcy restructuring” (Mar&nbsp;19&nbsp;2024)
          </a>
          <span>Reports on Endo’s plan confirmation, lender ownership and settlement funding.</span>
        </li>
        <li>
          <a href="https://www.justice.gov/archives/opa/pr/opioid-manufacturer-endo-health-solutions-inc-ordered-pay-1536b-criminal-fines-and" target="_blank" rel="noopener noreferrer">
            U.S. Department of Justice – Endo Health Solutions misbranding case (May&nbsp;3&nbsp;2024)
          </a>
          <span>Describes the criminal fines and forfeiture related to misbranded Opana&nbsp;ER.</span>
        </li>
        <li>
          <a href="https://www.biopharmadive.com/news/mallinckrodt-bankruptcy-chapter-11-opioids/586836/" target="_blank" rel="noopener noreferrer">
            BioPharma Dive – “Mallinckrodt, beset by opioid drug suits, files for bankruptcy” (Oct&nbsp;12&nbsp;2020)
          </a>
          <span>Provides context on how opioid lawsuits and Acthar-related disputes led to Mallinckrodt’s first Chapter&nbsp;11 filing.</span>
        </li>
        <li>
          <a href="https://www.ag.ky.gov/pdf_news/20171106_Complaint.pdf" target="_blank" rel="noopener noreferrer">
            Kentucky Attorney General – Complaint against Endo
          </a>
          <span>Alleges deceptive marketing of Opana and Opana&nbsp;ER and sets out the state’s theory of Endo’s role in the opioid crisis.</span>
        </li>
      </ul>

      <div class="subsection" style="margin-top:16px;">
        <div class="subsection-title">Merger, spin-off and business-press coverage</div>
      </div>
      <ul class="sources-list">
        <li>
          <a href="https://www.ft.com/content/86ad051e-94d3-4003-8f99-737dd7662400" target="_blank" rel="noopener noreferrer">
            Financial Times – “Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis”
          </a>
          <span>Frames the merger and provides details on valuation, opioid settlements and the companies’ post-bankruptcy context.</span>
        </li>
        <li>
          <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-mallinckrodt-endo-merge-nearly-7-billion-deal-2025-03-13/" target="_blank" rel="noopener noreferrer">
            Reuters – “Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal” (Mar&nbsp;13&nbsp;2025)
          </a>
          <span>Covers the announcement, enterprise value, expected revenue and NYSE listing plans.</span>
        </li>
        <li>
          <a href="https://www.marketwatch.com/story/mallinckrodt-and-endo-to-combine-in-6-7-billion-stock-and-cash-deal-0b9084f9" target="_blank" rel="noopener noreferrer">
            MarketWatch – Mallinckrodt &amp; Endo to combine in $6.7&nbsp;billion deal
          </a>
          <span>Provides additional details on structure and rationale of the transaction.</span>
        </li>
        <li>
          <a href="https://www.investopedia.com/drugmakers-mallinckrodt-endo-to-merge-plan-nyse-listing-11696081" target="_blank" rel="noopener noreferrer">
            Investopedia – “Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing”
          </a>
          <span>Explains the expected listing, enterprise value and pro forma portfolio.</span>
        </li>
        <li>
          <a href="https://www.mallinckrodt.com/" target="_blank" rel="noopener noreferrer">
            Mallinckrodt.com – corporate site (Keenova / Par Health information)
          </a>
          <span>States the July&nbsp;31&nbsp;2025 merger closing date and November&nbsp;2025 spin-off and rebrand into Keenova and Par Health.</span>
        </li>
        <li>
          <a href="https://pharmaphorum.com/news/irelands-mallinckrodt-closes-spinout-rebrands-keenova" target="_blank" rel="noopener noreferrer">
            Pharmaphorum – “Ireland’s Mallinckrodt closes spinout, rebrands as Keenova” (Nov&nbsp;2025)
          </a>
          <span>Provides pro forma sales, headcount and positioning for Keenova and Par Health.</span>
        </li>
        <li>
          <a href="https://www.biospace.com/press-releases/par-health-completes-spin-off-from-mallinckrodt-creating-an-independent-leader-in-generic-pharmaceuticals-and-sterile-injectables" target="_blank" rel="noopener noreferrer">
            BioSpace / PR Newswire – “Par Health completes spin-off from Mallinckrodt…”
          </a>
          <span>Describes Par Health’s generics, API and sterile injectables focus and manufacturing footprint.</span>
        </li>
        <li>
          <a href="https://www.fiercepharma.com/pharma/merger-books-mallinckrodt-and-endo-rebrand-keenova-spin-generics-business-par-health" target="_blank" rel="noopener noreferrer">
            FiercePharma – coverage of Keenova rebrand &amp; Par Health spin-off
          </a>
          <span>Frames the combined group’s repositioning after opioid-related pressures and restructurings.</span>
        </li>
      </ul>
    </div>
  </section>

  <section class="section" id="disclosure">
    <div class="disclosure">
      <p>
        <strong>Prepared by:</strong> Ted Nawrocki. This site is an independent synthesis of public information from the sources
        above. It is for educational and informational purposes only and does not provide investment, legal, tax, accounting or
        medical advice, nor any recommendation regarding any security, issuer or transaction.
      </p>
    </div>

    <footer>
      <div>© 2025 Ted Nawrocki. All rights reserved.</div>
      <div>All trademarks and company names are the property of their respective owners.</div>
    </footer>
  </section>
</main>

<script src="script.js"></script>
</body>
</html>
